IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells. The Phase 1 trial is designed to evaluate...
PDUFA target action date set for April 28, 2027 Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation...
IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload Immunome ADC...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation...
Varegacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints Varegacestat demonstrated statistically significant improvement...
Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s...
New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors Detailed...
Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...
Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...